volv.swiss

Analisi sito web volv.swiss

 Generato il Dicembre 08 2025 14:08 PM

Statistiche non aggiornate? AGGIORNA !

Il punteggio e 54/100

SEO Content

Title

Volv Global | Towards better healthcare

Lunghezza : 39

Perfetto, il tuo title contiene tra 10 e 70 caratteri.

Description

Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.

Lunghezza : 130

Grande, la tua meta description contiene tra 70 e 160 caratteri.

Keywords

Molto male. Non abbiamo trovato meta keywords nella tua pagina. Usa questo generatore gratuito online di meta tags per creare keywords.

Og Meta Properties

Buono, questa pagina sfrutta i vantaggi Og Properties.

Proprieta Contenuto
locale en_GB
type website
title Volv Global | Towards better healthcare
description Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.
url https://volv.global/
site_name Template
updated_time 2025-11-11T22:19:39+01:00

Headings

H1 H2 H3 H4 H5 H6
1 13 57 0 0 0
  • [H1] Where technology meets Human
  • [H2] Shaping the future today for a better tomorrow
  • [H2] Volv Global’s suite of services
  • [H2] Improving lives with better tools and treatments
  • [H2] Insights & Events
  • [H2] Insights & Events
  • [H2] Case studies
  • [H2] How we help you
  • [H2] inTrigue
  • [H2] What we do
  • [H2] Insights
  • [H2] Meet Volv Global
  • [H2] inTrigue
  • [H2] Meet Volv Global
  • [H3] Personalise the patient journey
  • [H3] Target patient populations
  • [H3] Expand medical knowledge
  • [H3] Healthcareefficiencies
  • [H3] Adding value through unprecedented insights
  • [H3] Impact across the product lifecycle​
  • [H3] Clinical Development
  • [H3] Value and Access, HEOR
  • [H3] Medical Affairs
  • [H3] Commercial Excellence
  • [H3] AI Powered Solutions for Rare Disease and Healthcare Innovation
  • [H3] Advanced, proprietary machine learning technology for patient-disease insights
  • [H3] We find more patients
  • [H3] We detect diseases at an earlier stage​
  • [H3] We predict patient outcomes
  • [H3] We stratify patient cohorts
  • [H3] MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification
  • [H3] Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
  • [H3] Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
  • [H3] PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation
  • [H3] Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025
  • [H3] Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs
  • [H3] MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification
  • [H3] Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
  • [H3] Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
  • [H3] PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation
  • [H3] Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025
  • [H3] Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs
  • [H3] Where Technology Meets Human: A Call to Unite Clinical Expertise and Real‑World Patient Voices
  • [H3] Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment
  • [H3] News Article: AI in healthcare
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] World Orphan Drug Congress Europe 2025 | Volv Global in Amsterdam
  • [H3] Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025
  • [H3] Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment
  • [H3] Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors
  • [H3] Unlocking the Full Impact of Breakthrough Therapies in Breast Cancer Through Earlier Detection
  • [H3] Progressive Pulmonary Fibrosis: Solving the Puzzle of Poor Disease Control
  • [H3] Conference Posters: ATS 2025, 17-21 May
  • [H3] Conference Poster: Swiss Biotech Day 2025, 5th-6th May
  • [H3] Unlocking the Power of EMR Data for Earlier Gastric Cancer Diagnosis and Risk Prediction
  • [H3] Press Release: Volv Global Expands Office Footprint to Power Next-Generation AI Innovation in Healthcare
  • [H3] A Rare Disease Day Message from Dr. Al Freedman
  • [H3] Where technology meets Human: Volv Global at the World Orphan Drug Congress USA 2025
  • [H3] News Article: Volv Global Tracks Nearly Undetectable Diseases
  • [H3] White Paper: The Path to Rare Disease Clinical Trial Innovation
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data

Images

Abbiamo trovato 14 immagini in questa pagina web.

4 attributi alt sono vuoti o mancanti. Aggiungi testo alternativo in modo tale che i motori di ricerca possano comprendere meglio il contenuto delle tue immagini.

Text/HTML Ratio

Ratio : 0%

Il rapporto testo/codice HTML di questa pagina e inferiore a 15 percento, questo significa che il tuo sito web necessita probabilmente di molto piu contenuto.

Flash

Perfetto, non e stato rilevato contenuto Flash in questa pagina.

Iframe

Molto male, hai usato Iframes nelle tue pagine web, questo significa che in contenuto inserito negli Iframe non puo essere indicizzato.

URL Rewrite

Buono. I tuoi links appaiono friendly!

Underscores in the URLs

Perfetto! Non sono stati rilevati underscores nei tuoi URLs.

In-page links

Abbiamo trovato un totale di 34 links inclusi 0 link(s) a files

Anchor Type Juice
Skip to content Interno Passing Juice
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification Externo Passing Juice
Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat Externo Passing Juice
Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification Externo Passing Juice
PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation Externo Passing Juice
Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025 Externo Passing Juice
Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs Externo Passing Juice
Where Technology Meets Human: A Call to Unite Clinical Expertise and Real‑World Patient Voices Externo Passing Juice
Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment Externo Passing Juice
News Article: AI in healthcare Externo Passing Juice
Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study Externo Passing Juice
World Orphan Drug Congress Europe 2025 | Volv Global in Amsterdam Externo Passing Juice
Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025 Externo Passing Juice
Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment Externo Passing Juice
Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors Externo Passing Juice
Unlocking the Full Impact of Breakthrough Therapies in Breast Cancer Through Earlier Detection Externo Passing Juice
Progressive Pulmonary Fibrosis: Solving the Puzzle of Poor Disease Control Externo Passing Juice
Conference Posters: ATS 2025, 17-21 May Externo Passing Juice
Conference Poster: Swiss Biotech Day 2025, 5th-6th May Externo Passing Juice
Unlocking the Power of EMR Data for Earlier Gastric Cancer Diagnosis and Risk Prediction Externo Passing Juice
Press Release: Volv Global Expands Office Footprint to Power Next-Generation AI Innovation in Healthcare Externo Passing Juice
A Rare Disease Day Message from Dr. Al Freedman Externo Passing Juice
Where technology meets Human: Volv Global at the World Orphan Drug Congress USA 2025 Externo Passing Juice
News Article: Volv Global Tracks Nearly Undetectable Diseases Externo Passing Juice
White Paper: The Path to Rare Disease Clinical Trial Innovation Externo Passing Juice
Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed Externo Passing Juice
Finding Patients for Rare Diseases: A Case Study Externo Passing Juice
Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data Externo Passing Juice
Legal Notice Externo Passing Juice
Privacy Policy Externo Passing Juice
Manage options Interno Passing Juice
Read more about these purposes Externo Passing Juice
inTrigue Externo Passing Juice
Meet Volv Global Externo Passing Juice

SEO Keywords

Keywords Cloud

consent meet insights intrigue global patient title manage preferences access

Consistenza Keywords

Keyword Contenuto Title Keywords Description Headings
patient 6
manage 5
insights 4
access 3
consent 3

Usabilita

Url

Dominio : volv.swiss

Lunghezza : 10

Favicon

Molto male. Non abbiamo trovato shortcut icon. Le icone sono una tra le tante semplici possibilita per attirare regolarmente visitatori al tuo sito.

Stampabilita

Non abbiamo riscontrato codice CSS Print-Friendly.

Lingua

Buono. La tua lingua dichiarata en.

Dublin Core

Questa pagina non sfrutta i vantaggi di Dublin Core.

Documento

Doctype

HTML 5

Encoding

Perfetto. Hai dichiarato che il tuo charset e UTF-8.

Validita W3C

Errori : 0

Avvisi : 0

Email Privacy

Attenzione! E stato trovato almeno un indirizzo mail in plain text. Usa antispam protector gratuito per nascondere gli indirizzi mail agli spammers.

Deprecated HTML

Grande! Non abbiamo trovato tags HTML deprecati nel tuo codice.

Suggerimenti per velocizzare

Eccellente, il tuo sito web non utilizza nested tables.
Molto male, il tuo sito web utilizza stili CSS inline.
Grande, il tuo sito web ha pochi file CSS.
Molto male, il tuo sito web ha troppi file JS (piu di 6).
Perfetto, il vostro sito si avvale di gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Ottimizzazione

XML Sitemap

Grande, il vostro sito ha una sitemap XML.

https://volv.global/sitemap_index.xml

Robots.txt

http://volv.swiss/robots.txt

Grande, il vostro sito ha un file robots.txt.

Analytics

Grande, il vostro sito ha uno strumento di analisi dei dati.

   Google Analytics

PageSpeed Insights

Dispositivo
Categorie

Website-SEO-Überprüfung

Website-SEO-Überprüfung e uno strumento di ottimizzazione per i motori di ricerca (seo tool) che serve per analizzare le tue pagine web